NASDAQ: BLFSBiolife Solutions Inc Stock
$24.11-0.60 (-2.43%)
Updated Apr 30, 2025
BLFS Price
$24.11
Fair Value Price
-$0.27
Market Cap
$1.13B
52 Week Low
$17.15
52 Week High
$29.55
P/E
-54.8x
P/B
3.25x
P/S
14.54x
PEG
N/A
Dividend Yield
N/A
Revenue
$82.25M
Earnings
-$20.18M
Gross Margin
65.3%
Operating Margin
-23.71%
Profit Margin
-24.5%
Debt to Equity
0.15
Operating Cash Flow
$8M
Beta
1.74
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
BLFS Overview
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BLFS's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
BLFS
Ranked#7 of 42
Ranked#7 of 42
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $65.68 | B | |
| $4.72 | B | |
| $207.09 | B |
Be the first to know about important BLFS news, forecast changes, insider trades & much more!
BLFS News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BLFS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BLFS ($24.11) is overvalued by 9,163.38% relative to our estimate of its Fair Value price of -$0.27 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BLFS ($24.11) is not significantly undervalued (9,163.38%) relative to our estimate of its Fair Value price of -$0.27 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BLFS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BLFS due diligence checks available for Premium users.
Valuation
BLFS fair value
Fair Value of BLFS stock based on Discounted Cash Flow (DCF)
Price
$24.11
Fair Value
-$0.27
Undervalued by
9,163.38%
BLFS ($24.11) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BLFS ($24.11) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BLFS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BLFS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-54.8x
Industry
40.62x
Market
29.18x
BLFS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.25x
Industry
3.73x
BLFS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BLFS's financial health
Profit margin
Revenue
-$3.4M
Net Income
$12.5M
Profit Margin
-363.9%
BLFS's Earnings (EBIT) of -$19.50M... subscribe to Premium to read more.
Interest Coverage Financials
BLFS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$399.5M
Liabilities
$50.6M
Debt to equity
0.15
BLFS's short-term assets ($148.76M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BLFS's short-term assets ($148.76M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BLFS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BLFS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$1.6M
Investing
$73.6M
Financing
-$3.7M
BLFS's operating cash flow ($8.43M)... subscribe to Premium to read more.
Debt Coverage Financials
BLFS vs Medical Stocks
Biolife Solutions Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.